# Competing endogenous RNA networks reveal long non-coding RNAs as potential prognostic biomarkers in gastric cancer: A systematic review and meta-analysis

Running title: lncRNAs as prognostic biomarkers in GC

Sadra Salehi-Mazandarani<sup>a</sup>, Mohammad Hossein Donyavi<sup>b</sup>, Amirhossein Vedaei<sup>c</sup>, Alireza Najimi<sup>d</sup>, Ziba Farajzadegan<sup>e</sup>, Parvaneh Nikpour<sup>a,\*</sup>

<sup>a</sup> Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>b</sup> Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

<sup>c</sup> Student Research Committee, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>d</sup> Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>e</sup> Department of Community and Family Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

\* **Correspondence should be addressed to:** Parvaneh Nikpour (PhD), Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Email: pnikpour@med.mui.ac.ir, Phone: 0098-31-37929143, Fax: 0098-31-36688597

Type of Article: Systematic review and meta-analysis

Total number of Words: 7610 (references included)

**Total number of Tables**: 2

**Total number of Figures**: 5

## Abstract

**Aims:** Gastric cancer (GC) represents a global health-care challenge. In recent years, a large number of competing endogenous RNA (ceRNA) network studies have elucidated critical long non-coding RNAs (lncRNAs) as potential prognostic biomarkers in GC. Nevertheless, there is no systematic review and meta-analysis regarding them. Here, we propose a systematic review and meta-analysis for lncRNAs as prognostic biomarkers based on the ceRNA network studies in GC.

**Main methods:** The Web of Science, Embase, PubMed, Scopus, ProQuest and Google Scholar databases were searched to collect eligible ceRNA network studies in which lncRNAs were reported as prognostic biomarkers until 27<sup>th</sup> June 2022. The pooled hazard ratios (HRs) were assessed to evaluate the prognostic effect of the lncRNAs. Prognostic values of highly reported lncRNAs were also examined. Furthermore, sensitivity analysis, and publication bias were evaluated.

**Key findings:** Totally, 35 studies were included in the systematic review among which 13 studies were eligible for meta-analysis. Pooled examination of HRs based on the univariate and multivariate reports revealed that the expression changes of the lncRNAs correlate with overall survival (OS) of GC patients. Two lncRNAs including *CCDC144NL-AS1* and *LINC01094* were highly reported as potential prognostic biomarkers based on the ceRNA network studies. Prognostic value of these two lncRNAs was furthermore confirmed by meta-analysis.

**Significance:** Our meta-analysis demonstrated potential application of lncRNAs introduced based on the ceRNA network studies as promising prognostic biomarkers in GC. Further functional studies are needed to elucidate the molecular mechanisms underlying these lncRNAs` functions in GC.

Keywords: competing endogenous RNA; gastric cancer; long non-coding RNA; overall survival

## **1. Introduction**

According to the information of the Global Cancer Observatory in 2020, gastric cancer (GC) had the sixth and fifth rates of incidence and mortality among the different types of cancers, respectively (1). Furthermore, GC was the sixth most prevalent cancer worldwide (1). The incidence of GC is variable among different countries and cultures (2). Most of the cases are diagnosed in eastern countries such as Japan and Korea where the population screening of GC is conducting. Although earlier detection and reduced *helicobacter pylori* (*HP*) infection in these countries have led to the decreased incidence of GC, it is still a serious concern (3). The 5-year survival rate of advanced GC in western countries, in which GC is mostly diagnosed at an advanced stage, is less than 10% (4). GC is a complex disease and many factors participate in its initiation and progression. The risk of GC has a direct correlation with increased ages and is higher in men rather than women. *HP* infects nearly half of the world spoulation and is a primary risk factor in GC. Some other risk factors for this type of cancer include blood type A, familial adenomatous polyposis (FAP) syndrome, Peutz–Jegher syndrome (PJS), salt intake, smoking, and alcohol (5).

Identification of novel non-invasive prognostic biomarkers with high sensitivity and specificity has always been a hot topic in the field of cancer research. Therefore, many studies have introduced novel prognostic biomarkers and evaluating their accuracy in GC. One of the promising type of prognostic biomarkers in GC which have recently received great attention are long non-coding RNAs (lncRNAs) (6).

IncRNAs are a group of non-coding RNAs with the length of longer than 200 nucleotides (7). Although they are not translated to proteins, they have critical physiological roles in cellular differentiation, stress, aging, proliferation, apoptosis and transcriptional regulation (8). Dysregulation of lncRNAs in cancers including GC have been identified (6). They affect tumor formation, progression, and metastasis (9). One of the most studied ways by which lncRNAs participate in tumorigenesis is their role as competing endogenous RNAs (ceRNAs). In fact, lncRNAs as well as other types of RNAs such as messenger RNAs (mRNAs) and circular RNAs

(circRNA) which have the same microRNA (miRNA) response elements (MREs) compete with each other for binding to the miRNAs (10). These crosstalk among various kinds of RNAs form the ceRNA networks that can promote tumorigenesis. The study of these networks can provide a deep view of molecular and cellular characteristics underlying GC progression and introduce novel prognostic biomarkers.

Over the last years, many studies have been conducted to identify ceRNA networks in GC. These studies mostly have some special steps consisting of data retrieval, identification of differentially-expressed RNAs (DERs), prediction of DERs interactions, ceRNA network construction, functional enrichment and finally survival analyses. Because of high accessibility to the different methods and databases for survival analysis of the RNA expression data, survival analysis has been somehow an inseparable part of ceRNA network studies. Utilizing The Cancer Genome Atlas (TCGA) (11) and gene expression omnibus (GEO) (12) data at most of the times, which have large sample sizes, can make the results of these studies, highly reliable. The survival analyses in these types of studies, have revealed the correlation between many lncRNAs and overall survival (OS) of GC patients. Due to the lack of a systematic review and meta-analysis regarding lncRNAs which have been reported as potential prognostic biomarkers from ceRNA network studies in GC, this meta-analysis set out to investigate the prognostic value of these lncRNAs in GC patients.

# 2. Materials and methods

#### 2.1. Guideline and registration

This study was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) (13). The review protocol was registered on The International Prospective Register of Systematic Reviews (PROSPERO) (CRD42022360864).

#### 2.2. Review Question

Which lncRNAs have been introduced as potential prognostic biomarkers in GC according to ceRNA network studies, and how much is their prognostic effect?

## 2.3. Selection criteria

Inclusion criteria included:

1. Having a ceRNA network including lncRNAs in GC

2. The number of at least one type of RNAs (lncRNA, miRNA, mRNA, etc) in the ceRNA network should be more than 1.

- 3. OS has been assessed.
- 4. Studies based on human samples

Exclusion criteria included:

- 1. Review studies
- 2. Studies not in English
- 3. Retracted studies
- 4. Studies not specified to GC
- 5. Studies without univariate survival analysis or its detailed results (after correspondence)
- 6. Congresses abstracts
- 7. Studies regarding a specific state of GC (For instance examination of HP infection in GC)

## 2.4. Literature Search Strategy

Online literature search was conducted up to 27<sup>th</sup> June 2022 in the Web of Science, Embase, PubMed, Scopus and Cochrane Central Library using a developed search query (Supplementary file 1). Grey literature was also searched on ProQuest and Google Scholar. Furthermore, reference lists of included studies were manually searched for studies potentially meeting the eligibility criteria. In case of missing information, authors were contacted via email.

## 2.5. Screening, quality assessment and data extraction

Records were imported to EndNote software ver. X8.0.1 and duplicate studies were removed. Two reviewers (SSM and MHD) independently screened title and abstracts of the studies to select relevant studies. Then, the full texts of the selected studies were assessed against inclusion and exclusion criteria. Any disagreement was solved through discussion with another reviewer (PN) until a consensus was reached.

After full text examination, the quality of the remained studies was assessed by Joanna Briggs Institute (JBI) critical appraisal checklist for cohort studies (14). Studies reached score of > 7 (each "yes" answer was considered as one score and "no" answers as zero), were selected as high quality and entered to the next step of data extraction.

An excel datasheet was designed for data extraction and two reviewers (SSM and MHD) independently extracted the data from the included studies. Extracted information consist of the name of the first author, year of publication, country of origin (the country of the corresponding author), origin of samples, sample size, the name of lncRNA(s), hazard ratio (HR), *p*-value, 95% confidence interval (CI), follow-up time and references. A third reviewer (PN) was consulted in case of disagreement. Univariate as well as multivariate OS analyses reports in which the correlation of one lncRNA with confounding factors such as age, gender, stage, etc were evaluated, were considered in the current study. Basis of HR examination (high expression group of lncRNA divided by low group or vice versa) were also considered.

## **2.6. Statistical analysis**

All analyses were performed using STATA software ver. 11.0. In all of the included studies to the meta-analysis part, the basis of HR examination was clear and similar (high expression group/low expression group). Two studies with unclear basis of HR calculation and the reference group (even after mailing) were excluded in meta-analysis (15, 16). The pooled examination of HRs with 95% CI of univariate survival results was performed based on the 11 studies, in which sample sizes were reported (17-27). Besides, according to the information of multivariate survival analysis, the pooled HRs with 95% CI was calculated. Four studies (23, 27-29) with

clear basis of HR examination were considered for pooled examination of multivariate reports. Furthermore, lncRNAs which were reported at least three times according to the univariate or multivariate survival analysis were meta-analized.

Forest plots were utilized to estimate the correlation of these lncRNAs expression with OS of GC patients.

 $l^2$  index was used to assess the between-study heterogeneity, If the heterogeneity was substantial ( $l^2$ >50%, *p*-value<0.05), the random effect model would be selected, otherwise, the fixed effect model would be utilized. lncRNAs with HR>1 and HR<1 were interpreted as risk and protective factors, respectively. For lncRNAs as risk factors, GC patients with higher expression of them, have shorter OS while for lncRNAs as protective factors, GC patients with higher expression of them have longer OS. *P*-value<0.05 was considered as statistically significant for the survival results. In addition, Begg's test was performed to assess the publication bias (30) and *p*value<0.05 were considered as significant publication bias.

Sensitivity analysis was performed for the lncRNAs obtained from multivariate analyses as well as lncRNAs which had been studied at least three times including univariate and multivariate analyses.

## **3. Results**

## **3.1.** Characteristics of the included studies

Out of 1764 initially identified studies through online and manual search, 1019 duplicates were removed, 684 studies were removed when screening title and abstracts and 21 studies were excluded though full-text reading. The quality of 40 remaining studies were examined and 5 studies did not pass this step due to having low quality (quality score  $\leq$ 7) (Supplementary file 2). Overall, 35 studies were recruited in the current study after selection by the mentioned criteria. The number of records at each step of the study selection process is shown in PRISMA flow chart (Figure 1).



Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of the search results and number of records at each stage

Excluded studies with the reason of exclusion are reported in supplementary file 3. Except one study (31), others had reported statistically significant prognostic lncRNAs (p-value<0.05), based on univariate survival analyses, which have been presented in table 1.

First author, Year (Reference)	Country	Origin of samples	lncRNA(s)	Follow-up (months)
Ye, 2022 (23)	China	TCGA	LINC01094	125
Huang, 2022 (29)	China	TCGA	CCDC144NL-AS1, HOXA10-AS, LINC01235	120
Huangfu, 2022 (27)	China	Clinical	<i>LINC00205</i>	96
		samples		
Tang, 2022 (17)	China	TCGA	NKX2-1-AS1, VCAN-AS1, AC010145.1, LINC00469,	120
			C15orf54, IGF2-AS, AC018781.1, LINC00052,	
			AL391152.1, POU6F2-AS2, ADAMTS9-AS1,	
			ADAMTS9-AS2, FLRT1	
Ji, 2022 (32)	China	GEPIA	LINC00922	120
Piao, 2022 (15)	China	Clinical	HYPAL	100
		samples		
Liao, 2021 (33)	China	TCGA	AC010145.1, AC018781.1, ADAMTS9-AS1,	120
			ADAMTS9-AS2, AL139002.1, AL391152.1, IGF2-AS,	
			LINC00326, POU6F2-AS2, VCAN-AS1, FRMD6-AS2,	
			C15orf54	
Wang, 2021 (34)	China	TCGA	ADAMTS9-AS2, PVT1	120
		GEPIA		
		UALCAN		117
Ye, 2021 (22)	China	TCGA	LINC02731, MIR99AHG, INHBA-AS1, LINC02613,	133
			CCDC144NL-AS1, VLDLR-AS1, LINC01497, LIFR-	
			AS1, A2M-AS1, LINC01537, LINC00702	
Zhang, 2021 (35)	China	TCGA	HMGA2-AS1, LINC01446, LINC01644, C7orf65,	100
			LINC01537, LINC01981, CASC20, LOC105373764,	
			ABCA9-AS1, LOC105375787, LINC02182,	
			LINC02266, LINC01697, LOC339260,	
			CCDC144NL.AS1, CYMP.AS1, LOC101929532,	
			LINC02042, HOXA11.AS, ADAMTS9-AS1,	
			LINC02657, LINC02389, LOC100506388,	
			LOC105369201, LINC02268, FLJ42969, TMEM132D-	
			AS1, LOC101928924, LINC01060, LINC02465,	
			LINC02269, LINC01606, LINC01592, LINC01146,	
			LINC01235	

**Table 1.** Significant prognostic value of the lncRNAs mentioned in the ceRNA network studies based on univariate survival analyses

Teng, 2021 (16)	China	Clinical	NKX2□1□AS1	100
		samples		
Fan, 2020 (24)	China	KM plotter	CCDC144NL-AS1	150
Peng, 2020 (36)	China	TCGA	HAND2-AS1	117
Sun, 2020 (18)	China	TCGA	LINC00330, AC061975.6, AP002478.1, ST7-AS2,	84
			AC123777.1, LINC00346, LINC00473, AC007389.1,	
			AL158206.1, LINC00365, PVT1, TM4SF19-AS1,	
			AC110491.1, DSCR4-IT1, LINC00460, AC011374.1,	
			HCG22	
Zhang, 2020 (28)	China	TCGA	MAGI2-AS3, HMGA1P4	120
Mao, 2020 (37)	China	TCGA	LINC01106, FOXD2-AS1, AC103702.2	133
		Clinical		50
		samples		
Liu, 2020 (38)	China	TCGA	ADAMTS9-AS1, C15orf54, AL391152.1	120
Li, 2020 (39)	China	TCGA	H19	100
		UALCAN		
Zu, 2020 (21)	China	TCGA, KM	DLGAP1-AS1, PVT1, RECQL4, HCG18	150
		plotter		
Qi, 2020 (40)	China	TCGA	AC018647.3, MAG12 AS3, MIR99AHG, NR2F1 AS1,	133
			LINC00106, PVT1, RP5 1074L1.4, RP11 7K24.3	
Nie, 2020 (25)	China	KM plotter	HCG18, SNHG16, H19, SNHG3, HNRNPU-AS1	150
Shen, 2020 (41)	China	UALCAN	H19	100
		Clinical		80
		samples		
Zhang, 2020 (42)	China	TCGA	LINC01235	133
Qi, 2019 (19)	China	GEO	LL22NC03-N14H11.1, RP3-428L16.2, LINC01105,	150
			LINC00982, LINC01094, MIR100HG, DNM3OS,	
			GATA6-AS1, RP11-363E7.4	
Peng, 2019 (43)	China	TCGA	MIR99AHG, AL139147.1	117
Pan, 2019 (20)	China	TCGA	ADAMTS9-AS2, ARHGEF26-AS1, HOTAIR, HOTTIP,	133
			LINC00052, NKX2-1-AS1, VCAN-AS1	
Zhang, 2019 (44)	China	TCGA	HMGA1P4	120
Yang, 2019 (45)	China	GEPIA	LINC01614, RP11-169F17.1, RP11-669N7.2	120
Zhu, 2019 (46)	China	TCGA	SNHG4, LINC00523	150
Wang, 2019 (47)	China	GEPIA	ADAMTS9-AS2	120
		TCGA		120
Arun, 2018 (48)	India	TANRIC	HOTAIR	-
Wang, 2018 (26)	China	KM plotter	RP11-363E7.4	150
He, 2018 (49)	China	TCGA	VCAN-AS1, IGF2-AS, ABCA9-AS1, ADAMTS9-AS1,	120
			ADAMTS9-AS2, AL391152.1, AL139002.1, C15orf54.	
			FRMD6-AS2	

Li, 2016 (50)	China	TCGA	RPLP0P2, FOXD2-AS1, H19, TINCR, SLC26A4-AS1,	67
			SMIM10L2A, SMIM10L2B, SNORD116-4	

\*GEO: Gene Expression Omnibus; GEPIA: Gene Expression Profiling Interactive Analysis; KM plotter: Kaplan Meier plotter; IncRNA: long non-coding RNA; TANRIC: The Atlas of Noncoding RNAs in Cancer; TCGA: The Cancer Genome Atlas; UALCAN: University of ALabama at Birmingham CANcer data analysis Portal

Supplementary file 4 contains the main characteristics of the 35 included studies. In all of the studies, a ceRNA network including lncRNAs were constructed and univariate/multivariate survival analysis were performed to identify correlation of lncRNA(s) with OS in GC. In table 1 and supplementary file 4, HR>1 and HR<1 represent shorter OS in patients with higher and lower expression of lncRNAs, respectively (The basis of HR examination in two studies (15, 16) were not clear). Six studies performed multivariate survival analysis based on evaluating the effect of one lncRNA with cofounding factors (Table 2).

HR	<b>P-value</b>	CI	Ref.
0.732	0.305	0.404-1.329	(23)
0.865	0.672	0.443-1.690	
0.868	0.734	0.384-1.962	
0.663	0.068	0.426-1.031	
0.788	0.437	0.432-1.437	
0.591	0.013	0.391-0.893	
4.313	<.001	2.867-6.489	
1.535	0.039	1.021-2.308	
1.82	0.001	1.26-2.63	(29)
1.32	0.333	0.75-2.34	
1.27	0.372	0.75-2.13	
1.37	0.190	0.86-2.2	
2.32	0.008	1.24-4.32	
1.79	0.001	1.25-2.57	
2.215	0.038	1.043-4.703	(27)
0.528	0.175	0.210-1.329	
0.956	0.892	0.497-1.837	
0.988	0.970	0.520-1.879	
0.923	0.858	0.385-2.212	
0.763	0.669	0.220-2.644	
6.674	0.006	1.713-26.001	
	HR 0.732 0.865 0.868 0.663 0.788 0.591 4.313 1.535 1.82 1.32 1.27 1.37 2.32 1.79 2.215 0.528 0.956 0.988 0.923 0.763 6.674	HRP-value0.7320.3050.8650.6720.8680.7340.6630.0680.7880.4370.5910.0134.313<.0011.5350.0391.820.0011.320.3331.270.3721.370.1902.320.0081.790.0012.2150.0380.5280.1750.9560.8920.9880.9700.9230.8580.7630.6696.6740.006	HRP-valueCI0.7320.3050.404-1.3290.8650.6720.443-1.6900.8680.7340.384-1.9620.6630.0680.426-1.0310.7880.4370.432-1.4370.5910.0130.391-0.8934.313<.0012.867-6.4891.5350.0391.021-2.3081.820.0011.26-2.631.320.3330.75-2.341.270.3720.75-2.131.370.1900.86-2.22.320.0081.24-4.321.790.0011.25-2.572.2150.0381.043-4.7030.5280.1750.210-1.3290.9560.8920.497-1.8370.9880.9700.520-1.8790.9230.8580.385-2.2120.7630.6690.220-2.6446.6740.0061.713-26.001

**Table 2.** Results of multivariate analysis in which the prognostic effect of one lncRNA has been analyzed with confounding factors

3.797	0.008	1.413-10.204	
3.273	< 0.001	1.652-6.592	
2.745	0.004	1.575-5.136	(16)
2.054	0.008	1.201-3.634	
1.934	0.003	1.245-3.121	
0.383	0.005	0.297-0.501	
1.429	0.102	0.931-2.194	(28)
0.973	0.865	0.710-1.334	
1.317	0.502	0.589-2.941	
1.084	0.518	0.850-1.382	
1.472	0.023	1.055-2.055	
1.14	0.60	0.70-1.84	(15)
0.83	0.64	0.39-1.79	
3.65	0.00	1.82-7.30	
0.27	0.00	0.12-0.59	
	3.797 3.273 2.745 2.054 1.934 0.383 1.429 0.973 1.317 1.084 1.472 1.14 0.83 3.65 0.27	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	3.797 $0.008$ $1.413-10.204$ $3.273$ $<0.001$ $1.652-6.592$ $2.745$ $0.004$ $1.575-5.136$ $2.054$ $0.008$ $1.201-3.634$ $1.934$ $0.003$ $1.245-3.121$ $0.383$ $0.005$ $0.297-0.501$ $1.429$ $0.102$ $0.931-2.194$ $0.973$ $0.865$ $0.710-1.334$ $1.317$ $0.502$ $0.589-2.941$ $1.084$ $0.518$ $0.850-1.382$ $1.472$ $0.023$ $1.055-2.055$ $1.14$ $0.60$ $0.70-1.84$ $0.83$ $0.64$ $0.39-1.79$ $3.65$ $0.00$ $1.82-7.30$ $0.27$ $0.00$ $0.12-0.59$

\*CI: confidence intervals; HR: hazard ratios; lncRNA: long non-coding RNA; M stage: Distant metastasis; N stage: Regional lymph nodes; T stage: primary tumor; TNM: Tumor, Node, and Metastasis

The original data of most of the studies were retrieved from TCGA database. The average follow-up time of the studies was 120 months. Except one (48), other studies were conducted in China. All articles were published between 2016 and 2022. The sample sizes among the included studies ranged from 50 to 876. In overall, studies reported statistically significant correlation of 122 unique lncRNAs with the prognosis of GC patients. Some of the studies used clinical samples and others utilized cancer databases including TCGA, GEO, GEPIA (51), UALCAN (52), KM plotter (53), and TANRIC (54).

#### 3.2. The prognostic significance of lncRNAs

Among studies with univariate survival analysis, 11 studies with reported sample size, HR (with clear basis of calculation), and CI were identified for meta-analysis (17-27). These studies included 70 lncRNAs (including unique and repeated lncRNAs). Higher expression of 57 and lower expression of 13 lncRNAs were associated with shorter OS. Studies with multivariate analysis reported four lncRNAs with clear basis of HR including *LINC01094*, *CCDC144NL-AS1*, *LINC00205*, and *MAGI2-AS3* (23, 27-29). The pooled HRs for univariate reports was 1.01 (95% CI 1.01-1.02, p-value<0.001, Figure 2).

ID		HR (95% CI)	% Weigh
Wang (RP11-363E7.4) (2018)	*	0.69 (0.55, 0.88)	0.11
QI (LL22NC03-N14H11.1) (2019)		1.29 (1.11, 1.50)	0.08
Qi (LINC01105) (2019)	+	0.70 (0.54 0.92)	0.14
Qi (LINC00982) (2019)	*	0.74 (0.59, 0.93)	0.10
Qi (LINC01094) (2019)	<b></b>	1.32 (1.06, 1.64)	0.04
Qi (MIR100HG) (2019)		1.15 (1.03, 1.28)	0.19
Qi (DNM3OS) (2019)		1.20 (1.03, 1.41)	0.08
QI (GATA6-AS1) (2019) Oi (PP11 363E7 4) (2010)		0.85 (0.73, 0.98)	0.19
Pan (ADAMTS9-AS2) (2019)	+	0.55 (0.39, 0.78)	0.20
Pan (ARHGEF26-AS1) (2019)		1.45 (1.00, 2.09)	0.01
Pan (HOTAIR) (2019)	ı —	1.60 (1.15, 2.22)	0.01
Pan (HOTTIP) (2019)		0.70 (0.51, 0.98)	0.05
Pan (LINC00052) (2019)		1.43 (1.02, 2.00)	0.01
Part ( $V(CAN_AS1)$ (2019) Part ( $V(CAN_AS1)$ (2019)		1.40 (1.03, 2.03)	0.01
Sun (LINC00330) (2020)	•	1.12 (1.06, 1.17)	0.88
Sun (AC061975.6) (2020)	•	1.07 (1.03, 1.11)	1.58
Sun (AP002478.1) (2020)	•	1.07 (1.02, 1.12)	1.09
Sun (ST7-AS2) (2020)	•	1.10 (1.03, 1.16)	0.60
Sun (AC123777.1) (2020)		1.82 (1.20, 2.78)	0.00
Sun (LINC00340) (2020) Sun (LINC00473) (2020)		1.02 (1.00, 1.03)	1.52
Sun (AC007389.1) (2020)		1.57 (1.07, 2.31)	0.01
Sun (AL158206.1) (2020)	•	1.00 (1.00, 1.01)	6.14
Sun (LINC00365) (2020)	•	1.03 (1.00, 1.06)	2.30
Sun (PV11) (2020)		0.99 (0.98, 1.00)	5.43
Sun (1043F19-AS1) (2020) Sun (AC110491 1) (2020)		1.07 (1.01, 1.14)	0.60
Sun (DSCR4-IT1) (2020)		1.33 (1.01, 1.76)	0.02
Sun (LINC00460) (2020)	•	1.02 (1.00, 1.04)	3.54
Sun (AC011374.1) (2020)		1.20 (1.00, 1.44)	0.06
Sun (HCG22) (2020)	•	1.01 (1.00, 1.02)	5.43
Zu (DLGAP1-AS1) (2020)		1.77 (1.43, 2.20)	0.02
Zu (RECOL4) (2020)	1	1.07 (1.34, 2.07)	0.02
Zu (HCG18) (2020)		2.07 (1.61, 2.67)	0.01
Nie (HCG18) (2020)	¦ →	2.07 (1.61, 2.67)	0.01
Nie (SNHG16) (2020)	· • • ·	1.45 (1.17, 1.80)	0.03
Nie (H19) (2020) Nie (SNILIC2) (2020)		1.96 (1.55, 2.48)	0.01
Nie (HNRNPLI-AS1) (2020)		1.37(1.10, 1.71)	0.02
Fan (CCDC144NL-AS1) (2020)		1.59 (1.23, 2.06)	0.02
Ye (LINC02731) (2021)	· · · · · · · · · · · · · · · · · · ·	1.53 (1.11, 2.10)	0.01
Ye (MIR99AHG) (2021)	· · · · ·	1.45 (1.05, 1.99)	0.01
Ye (INHBA-AS1) (2021)		1.42 (1.03, 1.95)	0.01
$Y_{e}$ (CCDC144NI -AS1) (2021)		1 44 (1 05, 2.03)	0.01
Ye (VLDLR-AS1) (2021)		1.38 (1.00, 1.90)	0.02
Ye (LINC01497) (2021)	i —	1.60 (1.16, 2.20)	0.01
Ye (LIFR-AS1) (2021)	· • • • • • • • • • • • • • • • • • • •	1.47 (1.07, 2.02)	0.01
Ye (A2M-AS1) (2021)		1.47 (1.07, 2.02)	0.01
$Y_{e}$ (LINC01557) (2021)		1.50 (1.09, 2.06)	0.01
Ye (LINC01094) (2022)		1.48 (1.06, 2.05)	0.01
Huangfu (LINC00205) (2022)		2.51 (1.38, 4.54)	0.00
Tang (NKX2-1-AS1) (2022)	•	1.00 (0.99, 1.00)	5.76
Tang (VCAN-AS1) (2022)	•	1.07 (1.03, 1.10)	2.20
Tang (LINC00460) (2022)		1.00 (0.98, 1.01)	4.04
Tang (C15orf54) (2022)	i i i	1.00(1.00, 1.01)	5.97
Tang (IGF2-AS) (2022)	•	1.00 (1.00, 1.00)	6.23
Tang (AC018781.1) (2022)	•	1.01 (1.00, 1.01)	6.01
Tang (LINC00052) (2022)	•	1.00 (0.98, 1.03)	2.88
lang (AL391152.1) (2022)		1.01 (1.00, 1.02)	5.51
Tang (POU6F2-AS2) (2022) Tang (ADAMTS9-AS1) (2022)		1.00 (1.00, 1.01)	5.97
Tang (ADAMTS9-AS2) (2022)		1.00 (1.00, 1.00)	6.31
Tang (FLRT1) (2022)	•	1.00 (0.98, 1.01)	3.87
Overall (I-squared = 84.1%, p = 0.000)		1.01 (1.01, 1.02)	100.00
NOTE: Weights are from random effects analysis			
1			

Figure 2. Forest plot of pooled examination of univariate survival results. CI: confidence interval; HR: hazard

ratio

The pooled HRs for multivariate was 1.60 (95% CI 1.27-1.94, *p*-value<0.001, Figure 3A).



Figure 3. Forest, sensitivity, and funnel plots of multivariate studies, Pooled HRs were calculated for four studies with multivariate analysis (a), Sensitivity analysis was performed for four studies with multivariate analysis (b), Begg's test was performed for four studies with multivariate analysis (c). HR: hazard ratio, lncRNA: long non-coding RNA CI: confidence interval

These results indicate that expression changes of the lncRNAs correlate with OS in GC and patients with higher expression of them have poorer survival.

### 3.3. CCDC144NL-AS1 and LINC01094 IncRNAs as prognostic biomarkers in GC

Two lncRNAs including *CCDC144NL-AS1* and *LINC01094* which were reported at least three times (based on the univariate and multivariate survival analysis) were identified. Forest plots of these lncRNAs have been presented (Figure 4a and 4b).



Figure 4. Forest, sensitivity, and funnel plots of two lncRNAs, Pooled HRs were calculated for CCDC144NL-AS1 (a) and LINC01094 (b), Sensitivity analysis was performed for CCDC144NL-AS1 (c) and LINC01094 (d), Begg's test was performed for CCDC144NL-AS1 (e) and LINC01094 (f). HR: hazard ratio, lncRNA: long non-coding RNA CI: confidence interval

Three ceRNA network studies have reported prognostic effects of *CCDC144NL-AS1* based on three univariate and one multivariate analyses (22, 24, 29). On the other hand, *LINC01094* was reported according to two studies based on two univariate and one multivariate analyses (19, 23). Forest plots revealed that the expression of both *CCDC144NL-AS1* (HR=1.56, 95% CI: 1.31-1.80, *p*-value<0.001, Figure 3B) and *LINC01094* (HR = 1.38, 95% CI: 1.15-1.62, *p*-value<0.001, Figure 3C) have negative association with OS.

## 3.4. Sensitivity analysis

We performed sensitivity analysis for studies with multivariate analysis (Figure 3b) as well as those studies reporting *CCDC144NL-AS1* (Figure 4c) and *LINC01094* (Figure 4d) lncRNAs, respectively, even though no heterogeneity was detected ( $I^2$ =0.0%, *p*-value>0.05). The results showed that this meta-analysis was reliable.

## 3.5. Publication bias

No significant publication bias was found in any of the univariate (Figure 5), multivariate (Figure 3c), and the two lncRNAs analyses (Figure 4e and 4f).



Figure 5. Funnel plot of pooled examination of studies with univariate survival results. HR: hazard ratio

The funnel plots are all symmetrical, demonstrating that there is no significant publication bias in this study. The *p*-value for Begg's test of univariate, multivariate, *CCDC144NL-AS1* and *LINC01094* were 0.183, 0.923, 0.174 and 0.117, respectively.

## **4.** Discussion

GC is one of the most common types of cancer around the world (1). Despite of currently treatment options such as surgery, chemotherapy, and radiotherapy, GC mainly reduces the quality of life (55). The overall relative survival rate of GC patients has been improved in the recent years, however it is still poor (56, 57). Therefore, identification of novel biomarkers to predict the survival rates of GC patients are needed.

In some ceRNA network studies, in which the competition among various types of RNAs for binding to the same miRNAs are examined, correlation of expression of ceRNAs with survival of GC patients has been evaluated (18, 21). To select the most relevant prognostic ceRNAs, researchers apply different strategies including selection of hub RNAs (mostly based on degree of centrality), differentially-expressed RNAs or RNAs interacting with other well-known RNAs.

Furthermore, most of these studies use databases like TCGA and GEO for data retrieval or analysis. These databases have mostly large sample size with long follow-up times which make their results highly reliable (58, 59). Up to now, a large number of ceRNA network studies have been published and many types of RNAs have been reported as potential prognostic biomarkers in GC. One of the most reported of these RNAs are lncRNAs. lncRNAs have been shown to be dysregulated in GC affecting GC cells progression, migration, metastasis, and apoptosis (60, 61).

To validate the accuracy of the reported lncRNAs as prognostic biomarkers in GC based on the ceRNA network studies, we conducted the current systematic review and meta-analysis. We searched literature looking for ceRNA network studies in GC which had reported lncRNAs as prognostic biomarkers. Thirty-five studies were with average follow-up time of approximately 120 months. Pooled examination of HRs based on both univariate and multivariate reports revealed that expression changes of lncRNAs, as ceRNAs, are correlated with OS of GC patients. Two lncRNAs entitled *CCDC144NL-AS1* and *LINC01094* were recurrently reported as GC prognostic biomarkers. Accordingly, we assessed prognostic values of them utilizing a meta-analysis approach and identified that overexpression of them correlates with poor OS in GC patients.

Among the included studies in the current meta-analysis, three (22, 24, 29) and two (19, 23) studies introduced *CCDC144NL-AS1* and *LINC01094* as prognostic biomarkers in GC, respectively. As mentioned above, three ceRNA network studies reported *CCDC144NL-AS1* as prognostic biomarker in GC. In 2022, Huang et al performed a ceRNA network study in GC and according to univariate and multivariate survival analysis, they introduced *CCDC144NL-AS1* as

a potential prognostic biomarker as its high expression was significantly associated with short OS (HR=1.5 (CI:1.09-2.09), Log-rank P=0.014) (29). Ye et al examined 378 GC samples from TCGA data and discovered *CCDC144NL-AS1* to be a potential biomarker for predicting GC prognosis. This was confirmed by univariate survival analysis (HR=1.4 (CI:1.04-1.99), *p*-value=0.018) and multivariate cox analysis (HR=1.4 (CI:1.04-1.99), *p*-value=0.006). Furthermore, this study discovered that this lncRNA affects proliferation, migration, and invasion of GC cells (22). In another study, researchers found that the expression level of *CCDC144NL-AS1* is higher in GC compared to normal tissues. This increase in expression is linked to the size of the tumor, a high rate of lymphatic spread, and a lower overall survival with a hazard ratio of 1.6 (CI:1.23-2.06) and a log-rank P value of 0.0035. Moreover, overexpression of *CCDC144NL-AS1* stimulates cellular proliferation, invasion, and migration of cancer cells in GC (24).

On the other hand, *LINC01094* was reported in two ceRNA network studies as a promising prognostic biomarker in GC. In one of the studies conducted by Ye et al, they used TCGA-STAD data that comprised of 370 samples. The results showed that the expression level of *LINC01094* is elevated in gastric cancer compared to normal tissues and found to be positively correlated with advanced stage. To determine the prognostic value of *LINC01094* expression, univariate and multivariate survival analyses were performed. The univariate analysis revealed a hazard ratio of 1.5 (95% CI: 1.06-2.05) with a *p*-value of 0.021, while the multivariate analysis resulted in a HR of 1.5 (95% CI: 1.02-2.30) and a *p*-value of 0.039. These findings indicate that elevated expression of *LINC01094* is associated with poor OS (23). In another study, Qi et al obtained data from 200 GC samples from the GEO database and demonstrated a correlation between the expression of *LINC01094* and OS. The HR was calculated to be 1.32 (95% CI: 1.06-1.64), with a significance level of 0.013 according to univariate survival analysis (19).

The importance of *CCDC144NL-AS1* and *LINC01094* have been also reported in other type of studies. By utilizing TCGA-STAD data, Sheng et al indicated that higher expression of *CCDC144NL-AS1* correlates with shorter OS in GC. Silencing of *CCDC144NL-AS1* significantly suppressed the cell proliferation and migration of GC cells, and also enhanced the

chemosensitivity of gastric cancer cells to 5-fluorouracil (62). In agreement with studies showing that higher expression of *CCDC144NL-AS1* is associated with shorter overall survival of patients with gastric cancer, the prognostic value of *CCDC144NL-AS1* has been furthermore implicated in several other types of cancers including non-small cell lung cancer (63), colorectal (64) and ovarian (65) cancers as well as renal cell carcinoma (66).

On the other hand, *LINC01094* expression has been shown to be correlated with metastasis, T and N stages as well as poor OS in GC. Besides, knockdown of *LINC01094* prevents cellular growth and migration in GC (67). In the same way, correlation of elevated levels of *LINC01094* with poor survival has been reported in various cancer types like ovarian (68), pancreatic (69), breast (70) and colorectal (71) cancer.

This meta-analysis had several strengths. Firstly, most of the included studies had large sample size as well as long follow-up time. Secondly, most of the evaluated lncRNAs had other important features in their reported studies like being differential-expressed, involving in cancerrelated pathways or having high degree centralities which further supports their role in cancer pathogenesis. Thirdly, there was a variation among the studies in the origin of samples (including TCGA, GEO, KM plotter, UALCAN, clinical samples, ...) which can potentially provide better evidence of the validity of the obtained results in our meta-analysis. However, there were also some limitations: 1) A large number of included studies did not have complete information (samples size, *p*-value, hazard ratio or confidence interval) even after sending emails and so subsequently could not be entered to meta-analysis. 2) Few studies had performed multivariate analysis which considers cofounding factors and makes the results more precise and reliable. 3) Although origin of samples generally varied between different studies, some of the included studies, had utilized common data or databases such as TCGA or KM plotter which supposed to lead to similar results among these studies. Of note, compared to these studies, number of researches with analyzing survival rate based on their own collected clinical samples were limited.

## **5.** Conclusions

In summary, the current study was the first systematic review and meta-analysis regarding the lncRNAs which have been introduced as potential prognostic biomarkers in GC based on ceRNA network studies. Many ceRNA network studies have revealed that dysregulation of lncRNAs expression may predict the survival rate of GC patients. In the current study, we systematically reviewed them and indicated this prognostic effect using meta-analysis. Furthermore, this meta-analysis indicated prognostic value of *CCDC144NL-AS1* and *LINC01094* in GC. Correlation of both of these lncRNAs with overall survival has been documented in other cancer types and seems that *CCDC144NL-AS1* and *LINC01094* are promising prognostic lncRNAs in the field of cancer. Further studies are required to validate the biological functions of these lncRNAs as prognostic biomarkers.

#### Acknowledgements

The Isfahan University of Medical Sciences in Isfahan, Iran, provided funding for this study.

#### Ethical Approval and Consent to participate

This study is a systematic review and meta-analysis which conducted meta-analysis on published papers reporting ceRNA networks mainly based on the data of TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/geo/) databases. The study protocol was approved by the Ethics Committee of Isfahan University of Medical Sciences and is available from here: https://ethics.research.ac.ir/ProposalCertificateEn.php?id=262634&Print=true&NoPrintHeader=true&NoPrintFooter=true&NoPrintPageBorder=true&LetterPrint=true.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors have no competing of interests to declare.

#### Availability of data and materials

This study is a systematic review and meta-analysis which conducted meta-analysis on published papers reporting ceRNA networks mainly based on the data of TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/geo/) databases.

#### **Funding statement**

The Isfahan University of Medical Sciences in Isfahan, Iran, provided funding for this study [grant number 140166].

## **CRediT** authorship contribution statement

Sadra Salehi-Mazandarani: Conceptualization, Investigation, Writing original draft, Writingreview & editing. Mohammad Hossein Donyavi: Investigation, Writing original draft, Writingreview & editing. Amirhossein Vedaei: Investigation, Writing original draft. Alireza Najimi: Formal analysis, Methodology, Writing original draft. Ziba Farajzadegan: Formal analysis, Methodology, Writing original draft. Parvaneh Nikpour: Supervision, Project administration, Writing original draft.

# References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-49. doi: https://doi.org/10.3322/caac.21660.

2. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny. 2019;14(1):26-38. Epub 2019/04/05. doi: 10.5114/pg.2018.80001. PubMed PMID: 30944675; PubMed Central PMCID: PMC6444111.

3. Sekiguchi M, Oda I, Matsuda T, Saito Y. Epidemiological Trends and Future Perspectives of Gastric Cancer in Eastern Asia. Digestion. 2022;103(1):22-8. doi: 10.1159/000518483.

4. Siebenhüner AR, De Dosso S, Helbling D, Astaras C, Szturz P, Moosmann P, et al. Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. Oncology Research and Treatment. 2021;44(9):485-94. doi: 10.1159/000518107.

5. Shah D, Bentrem D. Environmental and genetic risk factors for gastric cancer. Journal of Surgical Oncology. 2022;125(7):1096-103. doi: <u>https://doi.org/10.1002/jso.26869</u>.

6. Qian Y, Shi L, Luo Z. Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy. Frontiers in medicine. 2020;7:612393. Epub 2020/12/18. doi: 10.3389/fmed.2020.612393. PubMed PMID: 33330574; PubMed Central PMCID: PMC7734181.

7. Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biology. 2017;18(1):206. doi: 10.1186/s13059-017-1348-2.

8. Chen H, Shan G. The physiological function of long-noncoding RNAs. Non-coding RNA research. 2020;5(4):178-84. Epub 2020/09/23. doi: 10.1016/j.ncrna.2020.09.003. PubMed PMID: 32959025; PubMed Central PMCID: PMC7494506.

9. Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of IncRNA in cancer and therapeutic opportunities. American journal of cancer research. 2019;9(7):1354-66. Epub 2019/08/09. PubMed PMID: 31392074; PubMed Central PMCID: PMC6682721.

10. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353-8. Epub 2011/08/02. doi: 10.1016/j.cell.2011.07.014. PubMed PMID: 21802130; PubMed Central PMCID: PMC3235919.

11. Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics. 2013;45(10):1113-20. doi: 10.1038/ng.2764.

12. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002;30(1):207-10. Epub 2001/12/26. doi: 10.1093/nar/30.1.207. PubMed PMID: 11752295; PubMed Central PMCID: PMC99122.

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71. Epub 2021/03/31. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed Central PMCID: PMC8005924 at <a href="http://www.icmje.org/conflicts-of-interest/">http://www.icmje.org/conflicts-of-interest/</a> and declare: EL is head of research for the BMJ; MJP is an editorial board member for PLOS Medicine; ACT is an associate editor and MJP, TL, EMW, and DM are editorial board members for the Journal of Clinical Epidemiology; DM and LAS were editors in chief, LS, JMT, and ACT are associate editors, and JG is an editorial board member for Systematic Reviews. None of these authors were involved in the peer review process or decision to publish. TCH has received personal fees from Elsevier outside the submitted work. EMW has received personal fees from the American Journal for Public Health, for which he is the editor for systematic

reviews. VW is editor in chief of the Campbell Collaboration, which produces systematic reviews, and coconvenor of the Campbell and Cochrane equity methods group. DM is chair of the EQUATOR Network, IB is adjunct director of the French EQUATOR Centre and TCH is co-director of the Australasian EQUATOR Centre, which advocates for the use of reporting guidelines to improve the quality of reporting in research articles. JMT received salary from Evidence Partners, creator of DistillerSR software for systematic reviews; Evidence Partners was not involved in the design or outcomes of the statement, and the views expressed solely represent those of the author.

14. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. Joanna briggs institute reviewer's manual The Joanna Briggs Institute. 2017;5.

15. Piao HY, Liu Y, Kang Y, Wang Y, Meng XY, Yang D, et al. Hypoxia associated IncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2022;25(1):44-63. Epub 2021/07/12. doi: 10.1007/s10120-021-01213-5. PubMed PMID: 34247316.

16. Teng F, Zhang JX, Chen Y, Shen XD, Su C, Guo YJ, et al. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer. Molecular oncology. 2021;15(4):1234-55. Epub 2021/01/30. doi: 10.1002/1878-0261.12911. PubMed PMID: 33512745; PubMed Central PMCID: PMC8024734.

17. Tang S, Liao K, Shi Y, Tang T, Cui B, Huang Z. Bioinformatics analysis of potential Key IncRNAmiRNA-mRNA molecules as prognostic markers and important ceRNA axes in gastric cancer. American journal of cancer research. 2022;12(5):2397-418. Epub 2022/06/14. PubMed PMID: 35693096; PubMed Central PMCID: PMC9185605.

18. Sun D, Miao Y, Xu W, Shi W, Wang L, Chen T, et al. Comprehensive analysis of competitive endogenous RNAs network reveals potential prognostic lncRNAs in gastric cancer. Heliyon. 2020;6(5):e03978. doi: <u>https://doi.org/10.1016/j.heliyon.2020.e03978</u>.

19. Qi D, Wang Q, Wu M, Zhang X. Comprehensive bioinformatics analysis of lncRNAs in gastric cancer. Oncology letters. 2019;17(1):1279-91. Epub 2019/01/19. doi: 10.3892/ol.2018.9707. PubMed PMID: 30655896; PubMed Central PMCID: PMC6313033.

20. Pan H, Guo C, Pan J, Guo D, Song S, Zhou Y, et al. Construction of a Competitive Endogenous RNA Network and Identification of Potential Regulatory Axis in Gastric Cancer. Frontiers in Oncology. 2019;9. doi: 10.3389/fonc.2019.00912.

21. Zu F, Han H, Sheng W, Sun J, Zang H, Liang Y, et al. Identification of a competing endogenous RNA axis related to gastric cancer. Aging. 2020;12(20):20540-60. Epub 2020/10/21. doi: 10.18632/aging.103926. PubMed PMID: 33080572; PubMed Central PMCID: PMC7655175.

22. Ye L, Jin W. Identification of IncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma. Journal of clinical laboratory analysis. 2021;35(12):e24028. Epub 2021/10/28. doi: 10.1002/jcla.24028. PubMed PMID: 34704289; PubMed Central PMCID: PMC8649378.

23. Ye Y, Ge O, Zang C, Yu L, Eucker J, Chen Y. LINC01094 Predicts Poor Prognosis in Patients With Gastric Cancer and is Correlated With EMT and Macrophage Infiltration. Technology in cancer research & treatment. 2022;21:15330338221080977. Epub 2022/03/08. doi: 10.1177/15330338221080977. PubMed PMID: 35254147; PubMed Central PMCID: PMC8905065.

24. Fan H, Ge Y, Ma X, Li Z, Shi L, Lin L, et al. Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer. Cell Death & Disease. 2020;11(7):521. doi: 10.1038/s41419-020-02740-2.

25. Nie K, Zheng Z, Wen Y, Pan J, Liu Y, Jiang X, et al. A novel ceRNA axis involves in regulating immune infiltrates and macrophage polarization in gastric cancer. International immunopharmacology. 2020;87:106845. Epub 2020/08/09. doi: 10.1016/j.intimp.2020.106845. PubMed PMID: 32763781.

26. Wang P, Li J, Zhao W, Shang C, Jiang X, Wang Y, et al. A Novel LncRNA-miRNA-mRNA Triple Network Identifies LncRNA RP11-363E7.4 as An Important Regulator of miRNA and Gene Expression in Gastric Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;47(3):1025-41. Epub 2018/05/31. doi: 10.1159/000490168. PubMed PMID: 29843141.

27. Huangfu L, Fan B, Wang G, Gan X, Tian S, He Q, et al. Novel prognostic marker LINC00205 promotes tumorigenesis and metastasis by competitively suppressing miRNA-26a in gastric cancer. Cell Death Discovery. 2022;8(1):5. doi: 10.1038/s41420-021-00802-8.

28. Zhang X, Jiang Y, Xie Y, Leng X, Song F. Comprehensive Analysis of IncRNAs Associated with the Pathogenesis and Prognosis of Gastric Cancer. DNA and cell biology. 2020;39(2):299-309. Epub 2020/01/15. doi: 10.1089/dna.2019.5161. PubMed PMID: 31934786.

29. Huang Z, Liu X, Wu C, Lu S, Antony S, Zhou W, et al. A New Strategy to Identify ceRNA-Based CCDC144NL-AS1/SERPINE1 Regulatory Axis as a Novel Prognostic Biomarker for Stomach Adenocarcinoma via High Throughput Transcriptome Data Mining and Computational Verification. Frontiers in Oncology. 2022;11. doi: 10.3389/fonc.2021.802727.

30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101. Epub 1994/12/01. PubMed PMID: 7786990.

31. Guo Z, Liang E, Zhang T, Xu M, Jiang X, Zhi F. Identification and Validation of a Potent Multi-IncRNA Molecular Model for Predicting Gastric Cancer Prognosis. Frontiers in genetics. 2021;12:607748. Epub 2022/01/07. doi: 10.3389/fgene.2021.607748. PubMed PMID: 34987543; PubMed Central PMCID: PMC8720998.

32. Ji Z, Qiu Y, Cai Q, Xu C. LINC00922 acts as a novel oncogene in gastric cancer. World Journal of Surgical Oncology. 2022;20(1):121. doi: 10.1186/s12957-022-02569-3.

33. Liao Y, Cao W, Zhang K, Zhou Y, Xu X, Zhao X, et al. Bioinformatic and integrated analysis identifies an IncRNA-miRNA-mRNA interaction mechanism in gastric adenocarcinoma. Genes & genomics. 2021;43(6):613-22. Epub 2021/03/30. doi: 10.1007/s13258-021-01086-z. PubMed PMID: 33779949.

34. Wang S, Li XC, Zhu JR, Ma ZJ, Ran JT, Zhou YN. Construction of a novel ceRNA network and identification of lncRNA ADAMTS9-AS2 and PVT1 as hub regulators of miRNA and coding gene expression in gastric cancer. Translational cancer research. 2021;10(2):938-52. Epub 2022/02/05. doi: 10.21037/tcr-20-2168. PubMed PMID: 35116422; PubMed Central PMCID: PMC8799272.

35. Zhang S, Li S, Guo JL, Li N, Zhang CN, Liu J. Integrated Analysis of IncRNA-Associated ceRNA Network Identifies Two IncRNA Signatures as a Prognostic Biomarker in Gastric Cancer. Disease markers. 2021;2021:8886897. Epub 2021/10/05. doi: 10.1155/2021/8886897. PubMed PMID: 34603561; PubMed Central PMCID: PMC8479203.

36. Peng S, Yin X, Zhang Y, Mi W, Li T, Yu Y, et al. Competing endogenous RNA network analysis reveals potential long non-coding RNAs as predictive biomarkers of gastric cancer. Oncology letters. 2020;19(3):2185-96. Epub 2020/03/21. doi: 10.3892/ol.2020.11351. PubMed PMID: 32194716; PubMed Central PMCID: PMC7039062.

37. Mao R, Wang Z, Zhang Y, Chen Y, Liu Q, Zhang T, et al. Development and validation of a novel prognostic signature in gastric adenocarcinoma. Aging. 2020;12(21):22233-52. Epub 2020/11/15. doi: 10.18632/aging.104161. PubMed PMID: 33188157.

38. Liu M, Li J, Huang Z, Li Y. Gastric cancer risk-scoring system based on analysis of a competing endogenous RNA network. Translational cancer research. 2020;9(6):3889-902. Epub 2020/06/01. doi: 10.21037/tcr-19-2977. PubMed PMID: 35117756; PubMed Central PMCID: PMC8798172.

39. Li J, Wang X, Wang Y, Yang Q. H19 promotes the gastric carcinogenesis by sponging miR-29a-3p: evidence from IncRNA-miRNA-mRNA network analysis. Epigenomics. 2020;12(12):989-1002. Epub 2020/05/21. doi: 10.2217/epi-2020-0114. PubMed PMID: 32432496.

40. Qi M, Yu B, Yu H, Li F. Integrated analysis of a ceRNA network reveals potential prognostic IncRNAs in gastric cancer. Cancer medicine. 2020;9(5):1798-817. Epub 2020/01/11. doi: 10.1002/cam4.2760. PubMed PMID: 31923354; PubMed Central PMCID: PMC7050084.

41. Shen H, Wang L, Chen Q, Xu J, Zhang J, Fang L, et al. The prognostic value of COL3A1/FBN1/COL5A2/SPARC-mir-29a-3p-H19 associated ceRNA network in Gastric Cancer through bioinformatic exploration. Journal of Cancer. 2020;11(17):4933-46. Epub 2020/08/04. doi: 10.7150/jca.45378. PubMed PMID: 32742441; PubMed Central PMCID: PMC7378928.

42. Zhang X, Zheng P, Li Z, Gao S, Liu G. The Somatic Mutation Landscape and RNA Prognostic Markers in Stomach Adenocarcinoma. OncoTargets and therapy. 2020;13:7735-46. Epub 2020/08/18. doi: 10.2147/ott.s263733. PubMed PMID: 32801780; PubMed Central PMCID: PMC7414981.

43. Peng J, Zhu Y, Dong X, Mao X, Lou Y, Mu Y, et al. Construction and analysis of IncRNA-associated ceRNA network identified potential prognostic biomarker in gastric cancer. Translational cancer research. 2019;8(4):1116-28. Epub 2019/08/01. doi: 10.21037/tcr.2019.06.32. PubMed PMID: 35116854; PubMed Central PMCID: PMC8798625.

44. Zhang X, Zhang W, Jiang Y, Liu K, Ran L, Song F. Identification of functional IncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. Journal of cellular biochemistry. 2019;120(10):17898-911. Epub 2019/05/29. doi: 10.1002/jcb.29058. PubMed PMID: 31135068.

45. Yang J, Song H. Identification of long noncoding RNA RP11-169F17.1 and RP11-669N7.2 as novel prognostic biomarkers of stomach adenocarcinoma based on integrated bioinformatics analysis. Epigenomics. 2019;11(11):1307-21. Epub 2019/08/02. doi: 10.2217/epi-2019-0115. PubMed PMID: 31368349.

46. Zhu Y, Sun X, Lin J, Zhang T, Liu X, Shen X. Investigating Potential Molecular Mechanisms of Carcinogenesis and Genes as Biomarkers for Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis. Pathology oncology research : POR. 2019;25(3):1125-33. Epub 2018/11/16. doi: 10.1007/s12253-018-0523-4. PubMed PMID: 30430424; PubMed Central PMCID: PMC6614141.

47. Wang W, Li Z, Wang S. Identification of potential prognostic biomarkers for gastric adenocarcinoma by constructing competing endogenous RNA network. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE. 2019;12(11):12658-69.

48. Arun K, Arunkumar G, Bennet D, Chandramohan SM, Murugan AK, Munirajan AK. Comprehensive analysis of aberrantly expressed IncRNAs and construction of ceRNA network in gastric cancer. Oncotarget. 2018;9(26):18386-99. Epub 2018/05/03. doi: 10.18632/oncotarget.24841. PubMed PMID: 29719612; PubMed Central PMCID: PMC5915079.

49. Zhang Z, Wu S, Muhammad S, Ren Q, Sun C. miR-103/107 promote ER stress-mediated apoptosis via targeting the Wnt3a/ $\beta$ -catenin/ATF6 pathway in preadipocytes. Journal of lipid research. 2018;59(5):843-53. doi: https://doi.org/10.1194/jlr.M082602.

50. Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, et al. Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. International journal of oncology. 2016;48(5):1965-76. Epub 2016/03/05. doi: 10.3892/ijo.2016.3407. PubMed PMID: 26935047.

51. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids research. 2019;47(W1):W556-w60. Epub 2019/05/23. doi: 10.1093/nar/gkz430. PubMed PMID: 31114875; PubMed Central PMCID: PMC6602440.

52. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia (New York, NY). 2022;25:18-27. Epub 2022/01/26. doi: 10.1016/j.neo.2022.01.001. PubMed PMID: 35078134; PubMed Central PMCID: PMC8788199.

53. Lánczky A, Győrffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. Journal of medical Internet research. 2021;23(7):e27633. Epub 2021/07/27. doi: 10.2196/27633. PubMed PMID: 34309564; PubMed Central PMCID: PMC8367126.

54. Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, et al. TANRIC: An Interactive Open Platform to Explore the Function of IncRNAs in Cancer. Cancer research. 2015;75(18):3728-37. Epub 2015/07/26. doi: 10.1158/0008-5472.can-15-0273. PubMed PMID: 26208906; PubMed Central PMCID: PMC4573884.

55. Cai H, Li M, Deng R, Wang M, Shi Y. Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomarker Research. 2022;10(1):67. doi: 10.1186/s40364-022-00413-0.

56. Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. Journal of Surgical Oncology. 2022;125(7):1104-9. doi: <u>https://doi.org/10.1002/jso.26844</u>.

57. Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis. Cancer control : journal of the Moffitt Cancer Center. 2022;29:10732748221099227. Epub 2022/05/03. doi: 10.1177/10732748221099227. PubMed PMID: 35499497; PubMed Central PMCID: PMC9067041.

58. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary oncology (Poznan, Poland). 2015;19(1a):A68-77. Epub 2015/02/19. doi: 10.5114/wo.2014.47136. PubMed PMID: 25691825; PubMed Central PMCID: PMC4322527.

59. Wang Z, Lachmann A, Ma'ayan A. Mining data and metadata from the gene expression omnibus. Biophysical reviews. 2019;11(1):103-10. Epub 2018/12/31. doi: 10.1007/s12551-018-0490-8. PubMed PMID: 30594974; PubMed Central PMCID: PMC6381352.

60. Nasrollahzadeh-Khakiani M, Emadi-Baygi M, Schulz WA, Nikpour P. Long noncoding RNAs in gastric cancer carcinogenesis and metastasis. Briefings in functional genomics. 2017;16(3):129-45. Epub 2016/04/29. doi: 10.1093/bfgp/elw011. PubMed PMID: 27122631.

61. Gao Y, Wang JW, Ren JY, Guo M, Guo CW, Ning SW, et al. Long noncoding RNAs in gastric cancer: From molecular dissection to clinical application. World journal of gastroenterology. 2020;26(24):3401-12. Epub 2020/07/14. doi: 10.3748/wjg.v26.i24.3401. PubMed PMID: 32655264; PubMed Central PMCID: PMC7327794.

62. Sheng W, Zhou W, Cao Y, Zhong Y. Revealing the Role of IncRNA CCDC144NL-AS1 and LINC01614 in Gastric Cancer via Integrative Bioinformatics Analysis and Experimental Validation. Front Oncol. 2021;11:769563. Epub 2022/01/28. doi: 10.3389/fonc.2021.769563. PubMed PMID: 35083139; PubMed Central PMCID: PMC8784853.

63. Zhang L, Chi B, Chai J, Qin L, Zhang G, Hua P, et al. LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p. Molecular Biotechnology. 2021;63(10):933-40. doi: 10.1007/s12033-021-00351-6.

64. Zhang Y, Peng C, Li J, Zhang D, Zhang C, Jin K, et al. Long non-coding RNA CCDC144NL-AS1 promotes cell proliferation by regulating the miR-363-3p/GALNT7 axis in colorectal cancer. Journal of Cancer. 2022;13(3):752-63. Epub 2022/02/15. doi: 10.7150/jca.65885. PubMed PMID: 35154444; PubMed Central PMCID: PMC8824904.

65. Guo L, Peng Y, Meng Y, Liu Y, Yang S, Jin H, et al. Expression profiles analysis reveals an integrated miRNA-IncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2017;8(40):68483-92. Epub 20170726. doi: 10.18632/oncotarget.19590. PubMed PMID: 28978132; PubMed Central PMCID: PMC5620272.

66. Xu F, Ji S, Yang L, Li Y, Shen P. Potential upstream IncRNA-miRNA-mRNA regulatory network of the ferroptosis-related gene SLC7A11 in renal cell carcinoma. Translational andrology and urology. 2023;12(1):33-57. Epub 2023/02/11. doi: 10.21037/tau-22-663. PubMed PMID: 36760866; PubMed Central PMCID: PMC9906110.

67. Gong Z, Zhang Y, Yang Y, Yang Y, Zhang J, Wang Y, et al. LncRNA LINC01094 Promotes Cells Proliferation and Metastasis through the PTEN/AKT Pathway by Targeting AZGP1 in Gastric Cancer. Cancers. 2023;15(4):1261. PubMed PMID: doi:10.3390/cancers15041261.

68. Xu J, Zhang P, Sun H, Liu Y. LINC01094/miR-577 axis regulates the progression of ovarian cancer. Journal of ovarian research. 2020;13(1):122. Epub 2020/10/19. doi: 10.1186/s13048-020-00721-9. PubMed PMID: 33069244; PubMed Central PMCID: PMC7568364.

69. Luo C, Lin K, Hu C, Zhu X, Zhu J, Zhu Z. LINC01094 promotes pancreatic cancer progression by sponging miR-577 to regulate LIN28B expression and the PI3K/AKT pathway. Molecular therapy Nucleic acids. 2021;26:523-35. Epub 2021/10/12. doi: 10.1016/j.omtn.2021.08.024. PubMed PMID: 34631282; PubMed Central PMCID: PMC8479296.

70. Wu X, Kong C, Wu Y. Long intergenic non-protein coding RNA 1094 (LINC01094) promotes the progression of breast cancer (BC) by regulating the microRNA-340-5p (miR-340-5p)/E2F transcription factor 3 (E2F3) axis. Bioengineered. 2021;12(1):9046-57. Epub 2021/10/19. doi: 10.1080/21655979.2021.1993715. PubMed PMID: 34657558; PubMed Central PMCID: PMC8806954.

71. Zhang G, Gao Y, Yu Z, Su H. Upregulated long intergenic non-protein coding RNA 1094 (LINC01094) is linked to poor prognosis and alteration of cell function in colorectal cancer. Bioengineered. 2022;13(4):8526-37. Epub 2022/03/16. doi: 10.1080/21655979.2022.2051839. PubMed PMID: 35287563; PubMed Central PMCID: PMC9161846.